Koebenhavn N, Denmark

Birgit Wieczorek

USPTO Granted Patents = 13 

 

Average Co-Inventor Count = 5.1

ph-index = 5

Forward Citations = 71(Granted Patents)


Location History:

  • Copenhagen, DK (2015 - 2020)
  • Koebenhavn N, DK (2016 - 2021)
  • Koebenhavn, DK (2021)

Company Filing History:


Years Active: 2015-2021

Loading Chart...
Loading Chart...
13 patents (USPTO):Explore Patents

Title: Birgit Wieczorek: Innovator in GLP-1 Derivatives

Introduction

Birgit Wieczorek is a prominent inventor based in Koebenhavn N, Denmark. She has made significant contributions to the field of pharmaceuticals, particularly in the development of GLP-1 derivatives. With a total of 13 patents to her name, her work is pivotal in advancing treatments for diabetes and related diseases.

Latest Patents

Her latest patents focus on double-acylated GLP-1 derivatives. These derivatives are designed to enhance the efficacy of GLP-1 analogues, which are crucial in the treatment and prevention of diabetes. The invention details a derivative that includes specific K residues and a maximum of ten amino acid changes compared to GLP-1(7-37). The derivatives are engineered for oral administration, making them a promising option for patients.

Career Highlights

Birgit Wieczorek is currently associated with Novo Nordisk A/S, a leading global healthcare company. Her work at Novo Nordisk emphasizes her commitment to innovation in diabetes care. She has been instrumental in developing novel GLP-1 analogues that are suitable for pharmaceutical use.

Collaborations

Some of her notable coworkers include Lars Linderoth and Kilian Waldemar Conde Frieboes. Their collaborative efforts contribute to the advancement of research and development in the field of diabetes treatment.

Conclusion

Birgit Wieczorek's innovative work in GLP-1 derivatives showcases her dedication to improving healthcare solutions for diabetes. Her contributions are vital in the ongoing quest for effective treatments in this critical area of medicine.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…